roche building

Roche has launched the cobas MRSA/SA test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) from nasal samples.

The test is designed to run on the cobas 4800 system and detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Roche Molecular Diagnostics Head Paul Brown said with the addition of the cobas MRSA/SA test, the company offers clinicians a sustainable molecular test that will aid in the overall management of hospital-acquired infections.

"The cobas MRSA/SA Test combines laboratory procedures with automation, which provides labs with a simplified workflow through primary vial loading," Brown said. "This approach requires less hands-on time and reduces the chance of error, which leads to better patient management."

The test can process specimens using one of the fastest, most advanced real-time polymerase chain reaction (PCR) amplification and detection.

See Also:

The cobas 4800 system is reportedly the only CE-IVD marked system that offers the flexibility to run sexually transmitted infection and HAI tests simultaneously on a single platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Successful initiatives have led to a decrease in the rate of MRSA in many institutions, requiring optimal sensitivity and specificity for identifying true carriers."

According to the company, the streamlined workflow can help labs reduce time and costs, as well as improving the turnaround period.

University Hospital Regensburg Institute of Medical Microbiology and Hygiene professor Dr Udo Reischl said the fight against healthcare associated infections (HAIs) continues to develop.

"Successful initiatives have led to a decrease in the rate of MRSA in many institutions, requiring optimal sensitivity and specificity for identifying true carriers," Dr Reischl said.

"The cobas MRSA/SA Test demonstrates excellent performance in detecting diverse MRSA strains from around the world, which provides confidence in identifying infected patients the first time they are evaluated."

The cobas 4800 system’s expanding menu currently includes the cobas HSV 1 and 2 Test, cobas CT/NG Test (chlamydia/gonorrhea),cobas HPV Test, cobas BRAF V600 Mutation Test and the cobas EGFR Mutation Test.

Image: Aerial view of Roche Basel from south with river Rhine, Switzerland. Photo: courtesy of F Hoffmann-La Roche Ltd.